BioPharmaPT
← All reports

UCB — Rystiggo EMA EPAR public assessment report (EMEA/H/C/005824, 2024)

UCB · 2024 · EMA EPAR public assessment report · company profile →

Report summary

This EMA report assesses Rystiggo (rozanolixizumab) for generalized myasthenia gravis (gMG), an anti-FcRn monoclonal antibody. It details the regulatory process, manufacturing, quality control, and non-clinical studies confirming its mechanism and safety. Pharmacokinetic/pharmacodynamic modeling informed dosing, with clinical trials (MG0003, MG0007) demonstrating significant efficacy in improving gMG symptoms (MG-ADL, MG-Composite, QMG scores) at Day 43 for both 7mg/kg and 10mg/kg doses. Safety analysis revealed common adverse events like headache and infections, with higher incidence and severity at the 10mg/kg dose, leading to a recommended 7mg/kg regimen. The report concludes with a comprehensive risk management plan.

Key findings — cited to the page

Recommended weekly dose of Rystiggo for body weight ≥ 100 kg840 mgRystiggo · p.13
Scientific advice received from CHMP for rozanolixizumab development16/12/2021 rozanolixizumab · p.13
Scientific advice received from CHMP for rozanolixizumab development29/05/2019 rozanolixizumab · p.13
Concentration of rozanolixizumab in finished product140 mg/mL · p.14
Amount of rozanolixizumab per vial280 mg · p.14
Shelf life of rozanolixizumab active substance36 monthsrozanolixizumab · p.21
Protein concentration140 mg/mL · p.22
Strength280 mg/2 mL · p.22
Commitment to develop quantitative assay for free fatty acidsQ4 2024 · p.22
Commitment to investigate PS80 adsorptionend Q4 2024 · p.22
Shelf life24 months · p.25
Recommended weekly dose of Rystiggo for body weight ≥ 70 to < 100 kg560 mgRystiggo · p.13

Source: UCB · License: EMA - reuse permitted with acknowledgement. Summary and findings are extracted from the published document; every figure cites its page. Informational only — not investment advice. Explore the Immunology library →

UCB — Rystiggo EMA EPAR public assessment report (EMEA/H/C/005824, 2024) — Summary & Key Findings | BioPharmaPT